Topics


Glioblastoma | Treatment | Clinical trials






Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials






OVERVIEW




CHEMOTHERAPY


CARBOPLATIN





IRINOTECAN





LOMUSTINE

LURBINECTEDIN




METHOXYAMINE





NEOADJUVANT CHEMOTHERAPY





R-(-)-GOSSYPOL





TAXANES

TEMOZOLOMIDE






DIAGNOSIS / ASSESSMENT TOOLS


OLFACTORY FUNCTION

POSITRON EMISS TOMOGRAPHY






ELECTRIC AND MAGNETIC FIELDS


TUMOR TREATING FIELDS







GENE THERAPY


AGLATIMAGENE BESADENOVEC







IMMUNOTHERAPY


BISPECIF ANTIB ARMED T CELLS





CAR-T-CELLS

CELL THERAPY




DENDRITIC CELLS





GM-CSF





IMMUNE CHECKPOINT INHIBIT





VACCINES





VIRUSES







INTEGRATIVE MEDICINE


CIRCADIAN CLOCK





KETOGENIC METABOLIC THERAPY










LASER THERAPIES


LASER INTERSTITIAL THERMAL THER










NUCLEAR MEDICINE


THERANOSTICS







PHARMACOTHERAPY


ANTIEMETIC DRUGS

ANTIEPILEPTIC DRUGS

ANTISECRETORY FACTOR

ARSENICALS


CHLOROTOXIN





DISULFIRAM





IMMUNOSUPPRESSIVE DRUGS







RADIOTHERAPY


BORON NEUTRON CAPTURE THERAPY





EXTERNAL BEAM RADIATION THER





MARGINS





PHOTODYNAMIC THERAPY

PROTON BEAM




RADIOPHARMACEUTICALS

RADIOSENSITIZERS

RE-IRRADIATION

RESPONSE-ADAPTIVE




SURGERY


BIOPSY





FLAIRECTOMY

FLUORESCENCE-GUIDED SURGERY




RESECTION CAVITY

RESECTION EXTENT






TARGETED THERAPY


ADAVOSERTIB

AFATINIB

APTAMERS



ATEZOLIZUMAB





BEVACIZUMAB





DASATINIB

DRUG SCREENING




GLUTAMATE SIGN INHIBITORS





IPILIMUMAB





KHK2455

KINASE INHIBITORS




LENVATINIB

LISAVANBULIN




MARIZOMIB

MICROENV MODULATORS

MOGAMULIZUMAB



NAVTEMADLIN

NIVOLUMAB




OLAPARIB





PD-L1 TARGETED CANCER THERAPY

PEMBROLIZUMAB

PEXIDARTINIB



RINDOPEPIMUT

RO7428731




SACITUZUMAB GOVITECAN

SUNITINIB




TISLELIZUMAB





VELIPARIB